Figures & data
Table 1 Baseline characteristics of patients from Morocco and the Middle EastTable Footnotea
Figure 1 Patient disposition in the Morocco and Middle East cohorts.
Abbreviation: SD, standard deviation.
Table 2 Effect of acarbose treatment on mean change (Δ) in fasting blood glucose and one-hour PPBG from baseline to final visit in the Morocco and Middle East cohorts
Table 3 Mean ± standard deviation total change in FBG and one-hour PPBG from baseline to final visit in the Morocco and Middle East cohorts according to subgroups treated with acarbose
Figure 2 Effect of acarbose treatment on mean ± standard deviation (shown as vertical bars) change over time in (A) one-hour postprandial blood glucose (mg/dL) and (B) fasting blood glucose (mg/dL) in patients from Morocco and the Middle East.
Figure 3 Effect of acarbose treatment on HbA1c (mean ± standard deviation, shown as vertical bars) in patients from Morocco and the Middle East.
Table 4 Physician satisfaction, n (%) with (A) acarbose efficacy and (B) overall tolerability assessment
Table 5 Incidence (≥1.0%) of adverse events and adverse drug reactions in patients from Morocco and the Middle East treated with acarbose